Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 11, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	3,155	1,519	1,145	1,176	429	64
Market Cap Growth	97.19%	32.58%	-2.58%	173.76%	568.00%	321.43%
Enterprise Value	2,645	977	989	892	379	44
Last Close Price	32.60	19.17	21.78	29.21	19.77	16.45
PS Ratio	37.40	5028.17	3647.53	663.46	144.94	61.23
PB Ratio	8.53	2.26	2.59	2.98	2.29	0.54
P/TBV Ratio	9.91	3.15	4.86	4.65	7.97	-
EV/Sales Ratio	37.36	3236.51	3150.76	503.65	127.79	41.48
Debt / Equity Ratio	0.05	0.03	0.05	0.01	0.00	0.00
Asset Turnover	0.11	0	0.00	0.01	0.02	0.01
Quick Ratio	11.06	14.99	17.93	12.73	14.48	11.96
Current Ratio	11.28	15.43	18.27	12.93	14.68	12.14
Return on Equity (ROE)	-49.89%	-48.48%	-56.80%	-44.57%	-51.61%	-163.07%
Return on Assets (ROA)	-30.08%	-30.32%	-34.37%	-26.28%	-29.75%	-31.36%
Return on Capital (ROIC)	-32.26%	-32.26%	-36.80%	-28.52%	-32.28%	-35.04%
Return on Capital Employed (ROCE)	-61.70%	-43.10%	-54.90%	-33.40%	-41.90%	-33.60%
Earnings Yield	-7.88%	-17.78%	-20.76%	-11.05%	-18.49%	-172.21%
FCF Yield	-10.49%	-15.33%	-16.16%	-8.05%	-12.79%	-46.39%
Buyback Yield / Dilution	-34.66%	-51.68%	-39.48%	-169.22%	-235.07%	-70.27%

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q